Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|November 19, 2015
Thermo Fisher Scientific Opens New Singapore Location
Author(s)Pharmaceutical Technology Editors
Advertisement
On Nov. 18, 2015 Thermo Fisher Scientific Inc., a life sciences research company, announced the opening of their new GMP clinical services facility in Singapore. This new facility is meant to help meet the growing demand for clinical supply services in the region.
According to a press release from the company, Thermo Fisher Scientific Inc. opened its first clinical services facility in Singapore in 2001. The new facility will be located on Toh Guan Road, Jurong East and is nearly 70,000 ft2-60% larger than the previous site. The new site will provide pharmaceutical and biotech companies with clinical supplies including GMP storage, local labeling, secondary packaging, comparator sourcing, handling, and distribution of ambient and cold chain supplies.
Leon Wyszkowski, Thermo Fisher’s vice-president of Clinical Services for North America and facility network, says Singapore is the company’s fastest growing market and contributor to their growth. According to the company, clinical trial studies conducted in emerging Asian markets have increased in the past ten years, as a result of lower study costs and large patient populations.
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Complying with International Pharmacopoeias
5